Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Tabula Rasa HealthCare to $4 from $6 and keeps a Neutral rating on the shares. The company raised its fiscal 2022 revenue guidance on a Q3 sales beat but its operating losses widened considerably, Tassan tells investors in a research note. The analyst says questions about revenue mix and margin trends keep her on the sidelines.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TRHC:
- Tabula Rasa HealthCare Reports Third Quarter 2022 Results
- Tabula Rasa HealthCare names April Gill Chief Commercial Officer
- Tabula Rasa HealthCare adds Ron Mitchell to its board of directors
- Tabula Rasa HealthCare Co-President Brian Adams named interim CEO
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue